A concurrent $6 million financing included Commonwealth Capital, Oxford Bioscience, Flagship Ventures, Life Sciences Partners, FLIR Systems, Healthcare Ventures, New Science Ventures and HLM Venture Partners.
Jay Teich, CEO of Seahorse Bioscience, said: “Our sales of XF series instruments tripled in 2008, and we introduced three new products to this market at the end of the year. With the addition of the people and technologies of BioProcessors, we will expand and grow the SimCell product line and markets during the coming year.”